Synthesis and biological evaluation of novel hydrazide based cytotoxic agents

Expert Opinion on Investigational Drugs

Volumn 18, Issue 5, 2009, Pages 555-568

  Grande, Fedora ^a,b   Yamada, Roppei ^a   Cao, Xuefei ^a   Aiello, Francesca ^b   Garofalo, Antonio ^b   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Anticancer drugs; Hydrazides; Mechanism of activity; Novel cytotoxic agents

Indexed keywords

CYTOTOXIC AGENT; HYDRAZIDE DERIVATIVE; N' (7 FLUOROIMIDAZO[1,2 A]QUINOXALIN 4 YL)PYRAZINE 2 CARBOHYDRAZIDE; N' PYRIDO[3,2 E]PYRROLO[1,2 A]PYRAZIN 6 YLPYRAZINE 2 CARBOHYDRAZIDE; PACLITAXEL; PYRROLOQUINOXALINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE PROGRESSION; CHEMICAL MODIFICATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PHYSICAL CHEMISTRY; XENOGRAFT;

ANIMALS; CELL CYCLE; CYTOTOXINS; DRUG EVALUATION, PRECLINICAL; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; HYDRAZINES; MICE; MICE, NUDE; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649588597     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902858815     Document Type: Article

References (25)

1. Dy GK, Adjei AA. Obstacles and opportunities in the clinical development of targeted therapeutics. Prog Drug Res 2005;63:19-41 (Pubitemid 41406428)
2. Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008;20:104-111 (Pubitemid 350190989)
3. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 2007;13:4035-4041
4. Youssoufian H, Rowinsky EK. A remedy for biomarker addiction: back to rational anticancer drug development. Nat Clin Pract Oncol 2007;4:264-265 (Pubitemid 46758780)
5. Safavy A. Recent developments in taxane drug delivery. Curr Drug Deliv 2008;5:42-54 (Pubitemid 351225633)
6. Zhu F, Zheng CJ, Han LY, et al. Trends in the exploration of anticancer targets and strategies in enhancing the efficacy of drug targeting. Curr Mol Pharmacol 2008;1:213-232
7. Fan F, Wood KV. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 2007;5:127-136 (Pubitemid 46581246)
8. Neamati N, Barchi JJ Jr. New paradigms in drug design and discovery. Curr Top Med Chem 2002;2:211-227 • Review of modern aspects of drug design and discovery
9. Plasencia C, Dayam R, Wang Q, et al. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther 2005;4:1105-1113 •• First study disclosing anticancer properties of a series of salicylhydrazides.
10. Al-Mawsawi LQ, Dayam R, Taheri L, et al. Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2007;17:6472-6475
11. Grande F, Aiello F, Grazia OD, et al. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg Med Chem 2007;15:288-294 • First study describing an initial structure-activity relationship and cytotoxicity of a series of quinoxalinhydrazides.
12. Deng J, Taheri L, Grande F, et al. Discovery of novel anticancer compounds based on a quinoxalinehydrazine pharmacophore. ChemMedChem 2008;3:1677-1686 • First part of a series of papers describing a detailed computational approach used in optimizing quinoxalinhydrazide leads by designing novel scaffolds.
13. Cao X, Plasencia C, Kanzaki A, et al. Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis. Curr Cancer Drug Targets 2009. In press • A proteomic approach to understand the mechanism of action of salicylhydrazides.
14. Oshima T, Cao X, Grande F, et al. Combination effects of SC144 and cytotoxic anti-cancer agents. Anti Cancer Drugs 2009. In press • First details of synergistic studies between a lead quinoxalinhydrazide and conventional drugs.
15. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235-249 (Pubitemid 32239479)
16. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985;45:3668-3676 (Pubitemid 15226443)
17. Hamaguchi K, Godwin AK, Yakushiji M, et al. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 1993;53:5225-5232
18. Carmichael J, DeGraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-942
19. Munshi A, Hobbs M, Meyn RE. Clonogenic cell survival assay. Methods Mol Med 2005;110:21-28
20. Reich MF, Fabio PF, Lee VJ, et al. Pyrido[3,4-e]-1,2,4-triazines and related heterocycles as potential antifungal agents. J Med Chem 1989;32:2474-2485
21. Campiani G, Morelli E, Gemma S, et al. Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studies. J Med Chem 1999;42:4362-4379
22. Guillon J, Grellier P, Labaied M, et al. Synthesis, antimalarial activity, and molecular modeling of new pyrrolo[1,2-a]quinoxalines, bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2-a] pyrazines, and bispyrrolo[1,2-a]thieno[3,2-e]pyrazines. J Med Chem 2004;47:1997-2009
23. Kashulin IA, Nifant'ev IE. Efficient method for the synthesis of hetarenoindanones based on 3-arylhetarenes and their conversion into hetarenoindenes. J Org Chem 2004;69:5476-5479 (Pubitemid 39014386)
24. Van Hooser A, Goodrich DW, Allis CD, et al. Histone H3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation. J Cell Sci 1998;111( Pt 23):3497-3506 (Pubitemid 29015387)
25. Plasencia C, Grande F, Oshima T, et al. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity. Cancer Biol Ther 2009;8:458-465 • First disclosure of in vivo efficacy and broad-spectrum anticancer activity of a lead quinoxalinhydrazide.